Related references
Note: Only part of the references are listed.2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout
Pascal Richette et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
2020 American College of Rheumatology Guideline for the Management of Gout
John D. FitzGerald et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies
Carly A. Janssen et al.
RHEUMATOLOGY (2019)
Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval
Tristan Pascart et al.
RHEUMATOLOGY (2019)
Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial
Carly A. Janssen et al.
RHEUMATOLOGY (2019)
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study
Margareta Wiken et al.
CLINICAL RHEUMATOLOGY (2018)
Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels
Daniel H. Solomon et al.
ANNALS OF INTERNAL MEDICINE (2018)
Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature
A. Aouba et al.
MEDIATORS OF INFLAMMATION (2015)
Anakinra for the treatment of acute severe gout in critically ill patients
Jessica T. Thueringer et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
2015 Gout Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Tuhina Neogi et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures
J. D. Hirsch et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
Jasvinder A. Singh et al.
JOURNAL OF RHEUMATOLOGY (2014)
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial
Essack Mitha et al.
RHEUMATOLOGY (2013)
Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra
Pradipta Ghosh et al.
ARTHRITIS CARE & RESEARCH (2013)
Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
Sebastien Ottaviani et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator
Robert A. Terkeltaub et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial
H. Ralph Schumacher et al.
ARTHRITIS AND RHEUMATISM (2012)
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study
H. Ralph Schumacher et al.
ARTHRITIS CARE & RESEARCH (2012)
2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
Dinesh Khanna et al.
ARTHRITIS CARE & RESEARCH (2012)
Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout
Robert T. Keenan et al.
AMERICAN JOURNAL OF MEDICINE (2011)
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout
Ai P. Tran et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2011)
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study
Naomi Schlesinger et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Canakinumab for the Treatment of Acute Flares in Difficult-to-Treat Gouty Arthritis Results of a Multicenter, Phase II, Dose-Ranging Study
Alexander So et al.
ARTHRITIS AND RHEUMATISM (2010)
Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases
Kun Chen et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study
R. Terkeltaub et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Case of Anakinra as a Steroid-Sparing Agent for Gout Inflammation
Sarah B. Gratton et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
A pilot study of IL-1 inhibition by anakinra in acute gout
Alexander So et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
R. M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
S Cohen et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
